USPTO serial 87449309
DIMENSION THERAPEUTICS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- KHAN, AHSEN M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DIMENSION THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jessica S. Parise
JESSICA S. PARISE GOODWIN PROCTER LLP620 EIGHTH AVENUETHE NEW YORK TIMES BUILDINGNEW YORK, NY 10018Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo laboratory use in gene therapy | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of genetic diseases and disorders; Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, and fungal and viral diseases and disorders; pharmaceutical preparations for the treatment of cancer, pain, diabetes, damaged skin, damaged tissue and addiction; Gene therapy and prophylaxis products, namely, gene transfer, regulation, modulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disorders | ACTIVE | — |
| 042 | Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; diagnostics services in the field of equipment used for gene therapy design and delivery; gene therapy design and delivery development of biochemical assays | ACTIVE | — |
| 044 | Providing medical services, namely, gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, fungal and viral diseases and disorders; dispensing of pharmaceutical preparations for the treatment of cancer, pain, diabetes, damaged skin, damaged tissue and addiction | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Dimension Therapeutics, Inc.
- Other trademarks owned by Dimension Therapeutics, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named DIMENSION THERAPEUTICS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 10, 2018 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 10, 2018 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 8, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 13, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 13, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 21, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 7, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 7, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 7, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 7, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 7, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 14, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| May 18, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 18, 2017 | NWAP | NEW APPLICATION ENTERED | — |